These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15908183)

  • 1. Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.
    Lasser RA; Bossie CA; Gharabawi GM; Kane JM
    Schizophr Res; 2005 Sep; 77(2-3):215-27. PubMed ID: 15908183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-based and clinician-based support for the remission criteria in schizophrenia.
    Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
    Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
    Gastpar M; Masiak M; Latif MA; Frazzingaro S; Medori R; Lombertie ER
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):32-8. PubMed ID: 16144784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.
    Lasser RA; Bossie CA; Gharabawi GM; Baldessarini RJ
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):427-38. PubMed ID: 15804371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
    Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
    Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
    Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
    Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
    Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
    Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone.
    Gharabawi GM; Lasser RA; Bossie CA; Zhu Y; Amador X
    Int Clin Psychopharmacol; 2006 Jul; 21(4):233-40. PubMed ID: 16687995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting risperidone in stable patients with schizoaffective disorder.
    Mohl A; Westlye K; Opjordsmoen S; Lex A; Schreiner A; Benoit M; Bräunig P; Medori R
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):22-31. PubMed ID: 16144783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.
    Llorca PM; Sacchetti E; Lloyd K; Kissling W; Medori R
    Int J Clin Pharmacol Ther; 2008 Jan; 46(1):14-22. PubMed ID: 18218293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.
    Lambert M; De Marinis T; Pfeil J; Naber D; Schreiner A
    Eur Psychiatry; 2010 May; 25(4):220-9. PubMed ID: 19926263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
    Lasser R; Bossie CA; Gharabawi G; Eerdekens M; Nasrallah HA
    J Affect Disord; 2004 Dec; 83(2-3):263-75. PubMed ID: 15555724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
    Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O
    J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.